SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting in San Diego, CA, November 1-5, 2023. The details of the posters are as follows:
- Long-term efficacy and safety of lifileucel tumor infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study
- Poster: Saturday, Nov. 4, 2023, 9 a.m.–8:30 p.m. PT
- Tumor infiltrating lymphocytes (TIL) with inducible and membrane-bound IL-12 exhibit superior antitumor activity in vitro
- Poster: Friday, Nov. 3, 2023, 9 a.m.–7 p.m. PT
- Trial-in-Progress: TILVANCE-301, a phase 3 study of lifileucel tumor infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma
- Poster: Saturday, Nov. 4, 2023, 9 a.m.–8:30 p.m. PT
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit ...